Sensorion
Sensorion [ALSEN] is a biopharmaceutical company, formed in 2009, focused as a “pure player” on developing therapies for debilitating inner ear disorders. Sensorion’s mission is to offer innovative therapeutic solutions providing long-term improvements to people living with, or at risk of, inner ear disorders. Sensorion’s portfolio of solutions to unmet medical and social needs in inner ear disorders rests on three pillars – Restore, Treat, Prevent.
Sector
Biopharmaceuticals
Strategy
Crossover
Status
Active
Website
www.sensorion.com
Related Articles
Sensorion submits Clinical Trial Application for OTOF-GT, its lead gene therapy candidate, in Europe
Sonova invests €5 million in Sensorion as the companies plan a collaboration in hearing loss
Sensorion successfully raises approximately €31(US$ 36.5) million in an oversubscribed private placement to US and European investors
Sensorion appoints Dr Edwin Moses, former Ablynx CEO, as Chairman of the Board
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.